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Background: Metabolome analysis including amino acid profile is under investigation as an approach in cancer
screening. The present study aims to analyze plasma free amino acid (PFAA) profiles in cancer patients and
investigate their potential as biomarkers of malignancy.
Methods: Plasma samples from 56 gastric cancer patients, 28 breast cancer patients, 33 thyroid cancer patients,
and 137 age-matched healthy controls were collected in the study. PFAA levels were measured and their perioperative
alterations were analyzed. Biological effects of ten cancer-related amino acids were further validated in gastric and
breast cancer cells.
Results: We found that PFAA profiles of cancer patients differed significantly from those of healthy controls. Decreased
concentrations of PFAAs were associated with lymph node metastases in gastric cancer. Levels of PFAAs such as
aspartate and alanine increased after tumor resection. PFAA levels correlated with clinical tumor markers in gastric
cancer patients and pathological immunohistochemistry markers in breast cancer patients. Specifically, alanine, arginine,
aspartate and cysteine had proliferative effects on breast cancer cells. Proliferation of gastric cancer cells was promoted
by cysteine, but inhibited by alanine and glutamic acid. Furthermore, alanine treatment decreased total and stable
fraction of gastric cancer cells, and alanine and glutamic acid induced apoptosis of gastric cancer cells.
Conclusions: PFAA patterns in cancer patients are altered perioperatively. Tumor-related amino acids identified by
dynamic study of PFAA patterns may have the potential to be developed as novel biomarkers for diagnosis and
prognosis of cancer patients.
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Cancer will be the leading cause of death within the next
several decades, and the early detection of cancer is cru-
cial for improved survival of patients [1]. Current cancer
screening techniques such as endoscopy for gastric can-
cer (GC), mammography for breast cancer (BC), and
ultrasound for thyroid cancer (TC) are important in
clinical applications, although they are limited by inva-
siveness, radiation exposure and high cost [2-4]. Pre-
existing biomarkers such as carcinoembryonic antigen
(CEA) and carbohydrate antigen (e.g., CA 15–3 and
CA19-9) are also frequently used to monitor tumor* Correspondence: lsteng@zju.edu.cn; wangm198@hotmail.com
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unless otherwise stated.response, however, their sensitivities and specificities are
still controversial for early detection [5,6]. Therefore, novel
methods with noninvasiveness, reliable sensitivity and spe-
cificity are constantly desired for cancer screening.
Amino acids have been considered as potential targets
due to their roles as metabolites and metabolic regula-
tors. Recent studies have highlighted the diagnostic and
the prognostic potential of amino acids in a range of hu-
man diseases such as schizophrenia, chronic obstructive
pulmonary disease, and diabetes [7-9]. Cancer is viewed
as a metabolic disease with an enhanced metabolism,
since malignant cells require more amino acids to
synthesize proteins and nucleic acids [10,11]. Circulating
amino acids exhibited by plasma free amino acids (PFAAs)
may represent tumor-induced protein metabolism in
patients with malignancy [12]. Patients with cancer hads is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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PFAA profiles frequently correlated with the organ-site
origin among different cancers [18]. It is possible to moni-
tor and evaluate cancer patients before and after treatment
using a snapshot of amino acid metabolisms present at
time points [19]. However, there is limited information on
PFAA profiles of cancer patients during the perioperative
period and the influence of tumor removal on general
amino acid metabolisms is still largely unknown.
In the present study, we investigated the variation of
amino acids profiles between cancer patients and healthy
controls (HCs), by examining peripheral blood metabo-
lites from 56 GC patients, 28 BC patients, 33 TC pa-
tients, and 137 age-matched HCs. Tumor-specific PFAA
profiles were identified. Moreover, paired plasma sam-
ples were collected from 15 GC patients and 10 BC pa-
tients before intervention and 5–15 days after tumor
resection, and the perioperative PFAA levels were ana-
lyzed to reveal the effect of tumor burden on PFAA pro-
files. Cytological effects of tumor-related PFAAs on
gastric and breast cancer cells were further examined
in vitro. The present study demonstrates that dynamic
observations of PFAA profiles in cancer patients may
provide an insight into cancer metabolism and may be
an alternative to detect tumors.
Methods
Subjects
Data from 117 patients with GC, BC and TC were ana-
lyzed in the present study. The diagnoses of the primary
cancer were histologically made at the Cancer Center
of the First Affiliated Hospital, College of Medicine,
Zhejiang University, Hangzhou, China. One hundred
and thirty-seven HCs were recruited and screened for
serum levels of tumor markers, including carcinoem-
bryonic antigen (CEA), carbohydrate antigen19-9 (CA19-9),
carbohydrate antigen 125 (CA125), carbohydrate antigen
15–3 (CA15-3) and alpha-fetoprotein (AFP). The present
study was conducted according to the Declaration of
Helsinki and all procedures involving human subjects
were approved by the Medical Ethics Committee in the
First Affiliated Hospital, College of Medicine, Zhejiang
University. Verbal informed consent was obtained from all
subjects, witnessed, and formally recorded. Stages of GC,
BC, and TC were determined according to Tumor–
Node–Metastasis (TNM) Classification of Malignant
Tumors from the Seventh Edition of the American Joint
Committee on Cancer [20]. Clinical information listed in
Additional file 1 and Additional file 2 was obtained from
clinical records.
Cell culture
Human breast cancer cell lines MDA-MB-231 (Cat. No.
HTB-26), MCF7 (Cat. No. HTB-22) and BT-474 (Cat. No.HTB-20) and human gastric cancer cell line AGS
(Cat. No. CRL-1739) were obtained from American Type
Culture Collection (Manassas, VA, USA). Human gastric
cancer cell line SGC-7901 was obtained from the Cell Bank
of Type Culture Collection of the Chinese Academy of
Sciences (Shanghai, China) and human gastric cancer cell
line MKN45 was obtained from the Chinese Academy of
Medical Sciences Cancer Institute (Beijing, China). Cells were
cultured at 37°C in the presence of 5% CO2 in RPMI 1640
medium (Gibco BRL, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (HyClone, Logan, UT, USA).
PFAA analyses
Blood was collected from veins immediately after admis-
sion before the intervention and 5–15 days after tumor re-
section in patients with cancer who had an overnight fast.
Blood was placed in vacuum tubes with EDTA anticoagu-
lant (BD Biosciences, San Diego, CA, USA), and centri-
fuged at 1,000 × g for 10 min. Plasma was stored at −80°C
prior to use. Plasma concentrations of amino acids were
measured by Hitachi amino acid analyzer L-8800 (Hitachi
High-Tech, Tokyo, Japan) with colorimetric analysis as
previously described [21]. Briefly, the cryopreserved plasma
at 0.5 ml was added and mixed with 4% sulfosalicylic acid
at 1.5 ml, and then centrifuged at 26,900 × g for 15 min.
The supernatant at 0.02 ml was analyzed by the amino acid
analyzer with spectrophotometrical detection after postcol-
umn reaction with ninhydrin reagent. The flushing fluid
was 0.2 mM citric acid buffer at pH 3.3 and standard prod-
ucts and test kits were provided by the manufacturer. The
ammonia is measured using an automatic biochemical
analyzer Beckman CX9 (Beckman, Brea, CA, USA) with
enzymatic determination, according to the manufacturer’s
introductions. The amino acids and related molecules (18
compounds) measured in the analysis included alanine
(Ala), arginine (Arg), aspartate (Asp), cysteine (Cys), glu-
tamic acid (Glu), glycine (Gly), histidine (His), isoleucine
(Ile), leucine (Leu), lysine (Lys), methionine (Met), ammo-
nia (NH3), phenylalanine (Phe), proline (Pro), serine (Ser),
threonine (Thr), tyrosine (Tyr), and valine (Val). The
plasma levels of amino acids were expressed in μM. Proce-
dures of PFAA profiling were shown in Figure 1A.
Cell proliferation assay
Cell proliferation was measured by Cell Counting Kit-8
(CCK-8) detection kit (Dojindo, Kumamoto, Japan). Cells
were plated in 96-well plates at a concentration of 5 × 103
cells per well and incubated with Ala, Arg, Asp, Cys, Glu,
Gly, His, Ser, Thr, or Val at 10 mM for 24, 48, or 72 h, re-
spectively. The amino acids were purchased from Sigma-
Aldrich (St. Louis, MO, USA). After treatment, 10 μl of
CCK-8 per well was added and the cells were incubated at
37°C for 1 h. Proliferation was determined by absorbance
at 450 nm using ELx800 Absorbance Microplate Reader
Figure 1 (See legend on next page.)
Gu et al. Journal of Translational Medicine  (2015) 13:35 Page 3 of 14
(See figure on previous page.)
Figure 1 PFAA profiling of patients with cancers. Schematic procedures of PFAA screening (A) and PFAA profile alterations in 117 cancer
patients including 56 GC, 28 BC and 33 TC, compared to 137 HCs (B) are presented. Colored cells indicated levels of amino acids increased in
cancer patients at p < 0.001 (dark red), p < 0.05 (pink), decreased in cancer patients at p < 0.001 (dark green), p < 0.01(green) and p < 0.05 (light
green), respectively. PLS-DA scores plots showed a separation between control subjects (black) and cancer patients (red) in GC group (C), BC
group (D) and TC group (E). For GC group, R2 = 0.852, Q2 = 0.837; for BC group, R2 = 0.786, Q2 = 0.727; for TC group, R2 = 0.792, Q2 = 0.761. Altered
amino acid profiles of GC patients at early and advanced tumor stages are presented (F). The axes show the concentrations (μM) of each amino
acid for discriminating relative early stage from advanced stage. Blue line stands for PFAAs of GC patients at stage 0-III, red line for PFAA of GC
patients at stage IV. NEAAs: non-essential amino acids, EAAs: essential amino acids, BCAAs: branched-chain amino acids, GAAs: glucogenic amino
acids, TAAs: total amino acids, GC: gastric cancer, BC: breast cancer, TC: thyroid cancer, HC: healthy control.
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peated at least three times.
Dynamic monitoring of cell biobehaviors
Cells were plated into 24-well plates with a density of
1 × 104 cells per well, challenged with 10 mM Ala or
not, and imaged on Cell-IQ cell culturing platform
(Chip-Man Technologies, Tampere, Finland) every 5 min
for 72 h. Cell-IQ system uses machine vision technology
to monitor and record time-lapse data. It can also quan-
tify cell functions and morphological parameters, auto-
matically discriminate the dividing and stable cell stages,
and calculate the total cell numbers during proliferation
[22,23]. Differentiated cell is at the dividing cell stage
and appears round, and bright while cell is at the stable
cell stage and appears spindle and dark in Cell-IQ sys-
tem. Four visual fields per well were automatically se-
lected by the system. Total cell numbers and numbers of
stable and differentiated cells were analyzed by a freely
distributed Image software (Cell-IQ Imagen v2.9.5c,
McMaster Biophotonics Facility, Hamilton, Canada),
using the Manual Tracking plug-in created by Fabrice
Cordelieres (Institut Curie, Orsay, France).
Flow cytometry
Cell apoptosis was detected using the Annexin V-fluorescein
isothiocyanate (FITC)/propidium iodide (PI) apoptosis
detection kit (BD Biosciences) according to the manufac-
turer’s instructions. After treated with 10 mM Ala or Glu
for 48 h, cells (1 × 106/well) were collected, centrifuged,
and resuspended in 500 μl of 1 × binding buffer. Annexin
V-FITC (5 μl) and PI (5 μl) were then added to each
tube. The tubes were incubated in the dark at room
temperature for 20 min. Immediately after incubation, cell
apoptosis was assessed on a flow cytometry (BD Biosci-
ences). Representative images of experiments were shown.
All experiments were repeated at least three times.
Measurement of mitochondrial membrane potential
Mitochondrial membrane potential (MMP) was measured
using a fluorescent, lipophilic and cationic probe JC-1
(5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazol-
carbocyanineiodide) (Beyotime Biotech, Nantong, China)
according to the guideline from the manufacturer. Briefly,after indicated treatments, cells were incubated with JC-1
staining solution (5 μg/ml) for 20 min at 37°C and then
rinsed twice with PBS. The fluorescence intensity of JC-1
and its cellular distribution were imaged under a Leica
DMIRE2 confocal fluorescence microscope (Leica Micro-
systems AG, Wetzlar, Germany) equipped with Leica Con-
focal Software v.2.61. At least 6 visual fields in each were
examined by 2 independent investigators. Representative
images of experiments were shown. All experiments were
repeated at least three times.
Statistics
Differences among groups were analyzed by Student’s t-
test or one-way ANOVA, as appropriate. Paired-sample
t-test was applied to analyze differences of amino acid
concentrations of patients before and after tumor resec-
tion. Correlations between clinical characteristics and
amino acid concentrations were performed by Spearman’s
rho test and Pearson’s test, as appropriate. A two-tailed
value of p < 0.05 was considered statistically significant.
Statistical analyses were performed using SPSS 18.0
software (SPSS Inc., Chicago, IL, USA). Following data
normalization, the data set was input into SIMCA-P 11
software (Umetrics Inc., Umea, Sweden), partial least
squares-discriminant analysis (PLS-DA) was used to dis-
criminate between cancer patients and controls [16].
Results
Characteristics of subjects
The data sets comprised of 293 blood samples from 117
cancer patients, including 56 with GC, 28 with BC, 33
with TC, and 137 age- and gender-matched HCs. There
was no significant loss of patient body weight or signifi-
cantly decreased in serum albumin level before admission
to avoid potential influence of malnutrition-associated
metabolic changes (Additional file 1). The numbers of pa-
tients at each stage according to the type of cancer: were
subdivided as 16/56 (28.6%) at stages 0 and I, 5/56 (8.9%)
at stage II, 19/56 (33.9%) at stage III, and 12/56 (21.4%) at
stage IV in GC patients; 7/28 (25%) at stage I, 18/28
(64.3%) at stage II, 3/28 (10.7%) at stage III, and 0/28 at
stage IV in BC patients; 27/33 (81.8%) at stages 0 and I,
0/33 at stage II, 3/33 (9.1%) at stage III and 2/33 (6.1%) at
stage IV in TC patients, as shown in Table 1.
Table 1 Clinical characteristics of subjects
Characteristic Number
BC GC TC
Patients 28 56 33
Sex F/M 26/2 19/37 22/11
Age Mean (yrs) 57.5 61.9 45.0
Tumor size <=5 cm 26 29 32
>5 cm 2 23 1
Primary tumor T0-3 28 24 33
T4 0 28 0
Lymph nodes metastasis
MMEMmetastasis
Negative 15 21 19
Positive 13 31 14
Distant metastasis Negative 28 40 33
Positive 0 12 0
Stages# 0 0 2 0
I 7 14 27
II 18 5 0
III 3 19 3
IV 0 12 2
Uncharacterized 0 4 1
#Cancer stages were determined according to the International Union Against
Cancer TNM Classification of Malignant Tumors, 7th edition.
Table 2 Association of plasma free amino acid profiles with
lymph nodes metastasis status in gastric cancer patients
Lymph node metastasis
Negative Positive P-value
Asp 40.43 ± 8.84 39.65 ± 15.42 0.84
Thr 573.42 ± 151.47 482.93 ± 133.95 0.03*
Ser 184.48 ± 51.23 166.08 ± 54.06 0.22
Glu 143.20 ± 44.02 142.54 ± 51.59 0.96
Gly 314.26 ± 108.72 261.57 ± 85.22 0.06
Ala 402.78 ± 144.67 338.41 ± 115.88 0.08
Cys 57.73 ± 16.46 55.65 ± 19.27 0.69
Val 243.34 ± 59.76 223.94 ± 51.90 0.22
Met 34.85 ± 9.21 31.90 ± 10.38 0.30
Ile 77.43 ± 16.51 78.43 ± 26.45 0.88
Leu 152.75 ± 36.54 145.56 ± 37.56 0.50
Tyr 77.68 ± 33.21 75.80 ± 34.56 0.85
Phe 99.41 ± 22.06 90.22 ± 24.55 0.17
Lys 199.46 ± 48.14 175.67 ± 51.18 0.10
His 84.32 ± 22.81 71.23 ± 15.60 0.02*
Arg 113.70 ± 31.05 101.86 ± 40.30 0.26
Pro 96.68 ± 32.29 95.43 ± 41.45 0.91
NH3 139.91 ± 61.67 148.00 ± 60.06 0.64
NEAAs 1419.42 ± 328.68 1253.62 ± 355.51 0.10
EAAs 1380.65 ± 280.45 1213.08 ± 298.31 0.04*
BCAAs 473.52 ± 106.55 447.93 ± 107.62 0.40
GAAs 2213.05 ± 483.57 1923.79 ± 486.47 0.04*
TAAs 2939.98 ± 613.49 2614.70 ± 640.08 0.07
The plasma levels of amino acids were expressed in μM.
*Stands for p-values less than 0.05.
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patients with cancers
Alteration patterns in concentrations of PFAA in 117 can-
cer patients and 137 HCs were listed in Figure 1B. PFAA
profiles of patients with three types of cancers were signifi-
cantly different from those of HCs. Cancer patients
had significantly higher levels of Thr, Arg, and essential
amino acids (EAAs), and significantly lower levels of Asp,
Glu, Gly, Pro, non-essential amino acids (NEAAs), and
NH3, as compared to HCs (p < 0.05 or less, respectively,
Figure 1B and Additional file 3). Using PLS-DA we found
separation between groups of cancer patients and controls.
The scores plot shows each set of two groups scattering
into different regions, representing a good separation of
GC, BC or TC group from HC group with corresponding
plasma amino acid patterns (Figure 1C-E). The variation
of plasma amino acid profile at different disease stages
is considered to be important [12]. Most of BC and
TC patients in our study were categorized as early stage
and only a few were defined as advanced stage, as shown
in Table 1. In GC group, 12 cases were categorized as
advanced stage (stage IV), however, their PFAAs were not
significantly different from those at relative early stage
(stage 0-III) (Figure 1F and Additional file 4). When we
excluded data from GC patients at stage IV, PFAA profile
in GC patients at relative early stage (stage 0-III) is still
different from that in HCs (Additional file 5).Difference between types of cancers
Disease-specific alterations of amino acid profiles were
further explored by analyzing PFAA profile difference of
each cancer patients and HCs (Figure 1B). Level of His
was significantly lower in patients with BC. Levels of Ser,
Ala, Val, Lys, His, branched-chain amino acids (BCAAs),
glucogenic amino acids (GAAs), and total amino acids
(TAAs) were significantly lower in patients with GC. Pa-
tients with TC had significantly higher levels of Met,
Leu, Tyr, and Lys. PFAA alteration patterns of patients
with each type of cancer were different from each other
as shown in Additional file 3 and Additional file 5.
Association of PFAA profile with GC clinicopathological
characteristics
The association of plasma amino acid profiles with can-
cer clinicopathological characteristics, which includes
tumor size, invasiveness and metastasis, was further vali-
dated in the present study. Because most of BC and TC
patients were at relative early stages, we focused on the
Figure 2 (See legend on next page.)
Gu et al. Journal of Translational Medicine  (2015) 13:35 Page 6 of 14
(See figure on previous page.)
Figure 2 Dynamic alterations of PFAA profile during perioperative period. Perioperative alterations of PFAA levels in 15 patients with gastric
cancer (A) and 10 with breast cancer (B) are presented. *P < 0.05, as compared with those on day 0. Amino acids in cancer patients recovered to
normal level after tumor removal (C). *P < 0.05 versus HC. HC: healthy control, Pre: preoperation, Post: postoperation, Ala-BC: Ala of breast cancer
patients, Asp-BC: Asp of breast cancer patients, Asp-GC: Asp of gastric cancer patients.















*and **stand for p-values less than 0.05 and 0.01, respectively.
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stage cases. By comparing positive lymph node metasta-
ses group versus negative node metastases group, we
found that the concentrations of Thr, His, EAAs, and
GAAs were decreased (p < 0.05) (Table 2). Moreover, the
decrease in Thr level was significantly associated with
larger tumor size (>5 cm) and deeper invasion (T ≥ 4)
(p < 0.05) (Additional file 6).
Perioperative alterations of PFAA profiles
To identify perioperative alterations of PFAA profiles,
blood samples from 15 GC patients and 10 BC patients
were collected before the intervention, and 5–15 days
after tumor resection. Levels of His and Pro were signifi-
cantly decreased and levels of Phe and NH3 were signifi-
cantly increased in GC patients, 5-15days after surgery
(Figure 2A and Additional file 7). Levels of Asp, Ile, and
NH3 were significantly increased in BC patients, 6–14
days after surgery (Figure 2B and Additional file 7).
Level of Asp was significantly increased in GC and BC
patients after surgery, and Ala level showed a trend of
increase in BC patients after tumor removal (Figure 2C
and Additional file 7).
Correlation between cancer-related PFAAs and clinical
features of patients
PFAA levels in BC patients were significantly different
from those in HCs, while levels of CA15-3 and CA125
were still normal. In GC group, levels of many tumor
markers were higher than those in HCs, such as CA19-9
and CEA (as shown in Additional file 1). Levels of Cys
and Ile were significantly correlated with the level of
CA19-9, and levels of Glu, Ala, Arg, and Pro were sig-
nificantly correlated with the level of CEA in GC pa-
tients, as shown in Table 3. Level of Asp was correlated
with the level of AFP in GC patients. Information on
featured pathological parameters, such as estrogen re-
ceptor (ER), progesterone receptor (PR), human epider-
mal growth factor receptor 2 (HER-2), and Ki-67 was
also collected in BC patients (Additional file 1) and their
correlations with PFAAs were presented in Table 4.
Lower levels of Thr, Ser and Gly were significantly corre-
lated with positive ER status, lower level of Gly was sig-
nificantly correlated with positive PR status and higher
level of Ser was significantly correlated with positive
HER-2 status. Furthermore, lower level of Ile, Leu, His
and BCAA were associated with higher Ki-67 expression
in BC patients. Detailed data on correlations betweenother clinical features of patients with three types of
cancers and PFAA levels were shown in the Additional
file 2.
Effects of selected PFAAs on cell proliferation
To further investigate the functions of these altered
PFAAs identified from patients, 10 amino acids (Ala,
Arg, Asp, Cys, Gly, Glu, His, Ser, Thr and Val) were
chosen because they had the most obvious alterations in
GC and BC patients and significant correlation with pa-
tients’ clinicopathological parameters. Their effects on
GC cell line SGC-7901 and BC cell line MDA-MB-231
were examined in vitro, respectively. According to previ-
ous in vitro studies on amino acids, we chose concentra-
tion of 10 mM for each amino acid [24,25]. We assessed
cell viability at 24, 48 and 72 h after amino acid treat-
ments using CCK-8 proliferation assay. Among them,
Cys significantly promoted the proliferation of GC cells,
while Ala and Glu treatments inhibited cell proliferation
(Figure 3A). Ala, Cys, Asp, and Arg treatments could
stimulate the proliferation of BC cells (Figure 3B). Other
amino acids treatment did not show significant effects
on cell viability.
Effects of alanine on gastric and breast cancer cells
Above results reveal that Ala treatment showed opposite
effects on the proliferation of GC cell line SGC-7901
and BC cell line MDA-MB-231, suggesting that Ala may
be a key functional amino acid in different cancer me-
tabolisms. The effect of Ala on cell proliferation was fur-
ther examined in another two GC cell lines (AGS and
MKN45) and another two BC cell lines (MCF7 and BT-
474), respectively. Accordingly, Ala was found to inhibit
proliferation of AGS cells by 16% (48 h treatment) and
Table 4 Correlations between PFAAs and pathological
















*and **stand for p-values less than 0.05 and 0.01, respectively.
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MCF7 cells by 13% (48 h treatment) and 25% (72 h
treatment), and proliferation of BT-474 cells by 8% (72 h
treatment), respectively. A mild trend of proliferation in-
hibition was observed on the effect of Ala on MKN45
cells. Ala treatment inhibited the proliferation of SGC-Figure 3 Effects of different amino acids on cell viability of
gastric cancer and breast cancer cells. Gastric cancer cells
SGC-7901 were treated with Ala, Glu, Cys, or control medium (NC) at
10 mM (A) and breast cancer cells MDA-MB-231 were treated with
Ala, Cys,Asp, Arg or control medium (NC) at 10 mM (B), respectively,
for 72 h. Cell viability was determined using CCK-8 proliferation
assay. Data were presented as means ± SD of three independent
experiments and every experiment was performed in quintuplicate.
*P < 0.05 versus NC.7901 cells by 21% and increased the proliferation of MDA-
MB-231 cells by 29% after 72 h treatment (Figure 4A-C).
Because the results from SGC-7901 and MDA-MB-231
cell lines are more significant and promising, we next used
these two cell lines to study dynamic alterations of total
cell number, proliferation, division, apoptosis and migra-
tion after Ala treatment using Cell-IQ system to further
explore the potential function of Ala on cancer cells. Ala
treatment significantly reduced the numbers of total
(Figure 4D) and stable (Figure 4E) GC cells from 54 h and
on (p < 0.05), without an effect on BC cells (Figure 4G
and H). Ala did not affect the numbers of differenti-
ated GC cells (Figure 4F) or BC cells (Figure 4I).
Alanine and glutamic acid induced apoptosis of gastric
cancer cells
Since Ala and Glu treatments inhibited proliferation of
GC cells (Figure 3A), we next examined apoptosis of
three GC cell lines SGC-7901, AGS and MKN45 after
Ala or Glu treatment by flow cytometry. Apoptosis of
SGC-7901 and AGS cells were increased after treatment
with 10 mM Ala or Glu for 48 h (Figure 5A,B). Further-
more, we used SGC-7901 cells to assess the effect of Ala
on mitochondrial membrane potential (MMP) assay.
Mitochondria furnishes cellular energy through respir-
ation and regulates cellular metabolism to maintain the
growth, differentiation and proliferation of cells [26].
During apoptosis, MMP is depolarized, as an indicator of
mitochondrial dysfunction [26] and this can be detected
by JC-1 dye. In healthy cells, JC-1 accumulates in the
mitochondria with aggregated, red fluorescence, while in
apoptotic cells with decreased MMP, JC-1 is diffused in
the cytosol as green fluorescent monomers. Therefore a
decrease in the red/green fluorescence intensity ratio of
JC-1 staining indicates mitochondrial depolarization and
apoptosis. MMP was depolarized in GC cells after the
treatment of Ala or Glu at 10 mM for 24 h (Figure 5C,D).
Discussion
The plasma metabolic profiles have been investigated in
a variety of human cancers [27,28]. Our results sug-
gested that different tumor origins may lead to disease-
specific PFAA profile. Alterations of PFAA profiles were
closely correlated with clinical features of patients such
as molecular tumor markers in GC and hormone recep-
tors and Ki-67 expression in BC. In particular, concen-
trations of Thr, His, EAAs, and GAAs were significantly
correlated with lymph node metastases in patients with
GC, indicating that specific PFAAs may act as biological
indicators for the metastatic potential of GC. We further
found that levels of selected tumor-related metabolites
in cancer patients (such as Asp, Ala, His, Pro, Phe, Ile,
and NH3) dramatically changed 5–15 days after surgery.
In vitro, we examined cytological effects of 10 tumor-
Figure 4 (See legend on next page.)
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Figure 4 Biologic functions of Alanine on gastric and breast cancer cell lines in vitro. (A-C). Cell viability was assessed by CCK-8 proliferation
assay for indicated gastric cancer and breast cancer cells at 24 h (A), 48 h (B) and 72 h (C) after treatment with 10 mM Ala or negative control
medium (NC). (D-I). Dynamic changes of cell numbers were measured by Cell-IQ system. The numbers of total cells (D), stable cells (E) and
differentiated cells (F) from SGC-7901 cell line treated with 10 mM Ala or not. The numbers of total cells (G), stable cells (H) and differentiated
cells (I) from MDA-MB-231 cell line treated with 10 mM Ala or not. Ratios of cell numbers were calculated by formula: [values at indicated time
point – values at initial time point]/values at initial time point. Data were presented as means ± SD of three independent experiments. Every
CCK-8 assay was performed in quintuplicate and 24 measurements were evaluated in each group for Cell-IQ assay. *P < 0.05 versus NC.
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files on gastric and breast cancer cells. Among them, we
found that Ala and Glu inhibited the proliferation of GC
cells, while Ala promoted proliferation of BC cells. The
opposite effects of Ala on GC and BC cell indicate the
cancer specific role of Ala.
Although evidence of relationships between PFAA
profiles and certain types of cancer was introduced early,
only a few studies have investigated the use of PFAA
profiles for diagnosis. Recently Shingyoji et al. observed
high reproducibility of the discriminating performance
for patients with lung cancer compared to previously re-
ported results. Their results also show that combin-
ational application of PFAA profiles and tumor markers
may even improve the clinical utility of tumor markers
[29]. A Japanese research collecting samples from ap-
proximately 200 patients with lung, gastric, colorectal,
breast, or prostate cancer revealed significant differences
in the PFAA profiles between the controls and the pa-
tients with any of the five types of cancer listed above,
regardless of cancer stage [18]. Similar findings were ob-
served in patients with renal cell carcinoma [30] and
colorectal cancer [31]. These findings suggest that PFAA
profiling has great potential for improving cancer
screening and diagnosis and for understanding disease
pathogenesis. In addition, other studies have revealed
correlation between PFAA profiles and clinicopathologi-
cal characteristics such as pathological grading, lymph
node metastasis and clinical stage of patients with
esophageal squamous cell carcinoma [16] and cervical
cancer [32]. The longitudinal studies with larger sample
sizes and longer follow up are needed to further justify
whether PFAA might predict prognosis.
Previous reports have shown that ‘cachexia’ is an im-
portant cause of PFAA alterations of cancer patients,
which is a condition where patients lose body mass that
cannot be reversed nutritionally during the disease
course [33]. Cancer patients with cachexia had different
amino acid patterns from malnourished patients for
other reasons [34]. There is no sign of cachexia in our
subjects, as most of them did not lost weight or have de-
creased serum albumin level. Additionally, significant al-
terations in PFAA profiles were not observed in GC
patients between early stage and advanced stage. Thus,
it is reasonable to speculate that the identified changesof PFAA profiles do not result from poor nutrition
caused by tumor progression. Significant perturbations
of PFAA patterns in patients with cancer are usually
caused by dysfunctions of host metabolism [12]. Our
study demonstrated that GC patients had the most dis-
tinctive alterations since the majority of PFAA levels
seemed to decrease significantly. The difference from
other cancers may be related to absorption ability of the
gastrointestinal tract and hepatic metabolism in gastric
cancer patients [12]. Another proposed mechanism
might be the loss of protein-rich exudates into gastro-
intestinal tract from ulcerative cancer masses [12]. The
PFAA profile of BC patients is generally close to healthy
group among three types of cancer, which is in concord-
ance with previously reports [35]. This is probably be-
cause the growth rate and aggressiveness of BC are
lower than those of other metabolically active cancers
[36]. Notably, PFAAs pattern in TC patients was greatly
changed and this might be caused by upstream genomic
changes [37]. To our knowledge, this is the first study
reporting the PFAA profile of TC patients.
Lymph node metastasis is one of the most important
prognostic factors and provides important information
for accurate disease staging and appropriate treatments
for GC patients. However, preoperative diagnosis of
lymph node metastases has remained unsatisfactory [38].
Our results showed that Thr, His, EAAs, and GAAs
were significantly lower in lymph node positive GC pa-
tients compared with negative ones. Since Thr and His
were included in GAAs, the alteration might be due to
increased gluconeogenesis in GC with higher metastatic
potential. The decreased Thr level was also significantly
associated with larger tumor size (>5 cm) and deeper
tumor invasion (>T3), which suggests the important role
of Thr in GC development. Thr has been reported to de-
crease in many cancers including GC [12,18]. Thr can
be converted to pyruvate, which is located at a key inter-
section of metabolic network and has direct links to a
number of other amino acids [39,40]. However, larger
sample size is required to verify these observations.
PFAA profiling provides an instantaneous metabolic
snapshot of the human body [19]. It may be an effective
tool to monitor treatment response of patients. A previ-
ous study has shown that characteristic plasma amino
acid patterns of rats with tumors were reversed by
Figure 5 Alanine and glutamic acid induced apoptosis of gastric cancer cell line. (A-B). Induction of apoptosis was detected by flow
cytometry with Annexin V-PI staining. Representative flow cytometry plots demonstrating an increase in apoptosis of gastric cancer cell lines after
treatment with 10 mM Ala or Glu for 48 h (A). From parallel experiments, apoptosis was quantified (B). (C-D). Induction of apoptosis in SGC-7901
cells through dysregulation of the mitochondrial membrane potential. SGC-7901 cells were treated with 10 mM Ala, 10 mM Glu or negative
control (NC) for 24 h, respectively. Then the mitochondrial membrane depolarization of cells was examined by JC-1 dye staining with confocal
microscopy. Left and middle images showed green JC-1 monomer and red JC-1 aggregate, respectively. The right images showed the overlay of
two images. Green fluorescence indicates the presence of depolarized mitochondria (apoptotic cells). Red fluorescence indicates normally
functional and polarized mitochondria (healthy cells) (C). From parallel experiments, quantitative assessment of mitochondrial membrane
depolarization in SGC-7901 cells was presented as ratio of JC-1 aggregates/monomers (D). Data were represented as mean ± SD of three
independent experiments. *P < 0.05 versus NC.
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the dynamic metabolism of perioperative cancer patients
by PFAA profiling. After tumors were surgically removed,
preoperative deficiencies of Asp restored to normal levels
in both BC and GC patients. Similar alteration trend was
observed for Ala of BC patients. These preoperative defi-
ciencies of amino acids may be caused by increased uptake
and utilization of amino acids by tumor cells. PFAAs shall
be monitored until tumor recurrence and metastasis. If
these PFAAs drop again with tumor progression, it verifies
clinical significance of tumor-related amino acids. Trans-
location or redistribution of PFAAs in cancer patients to
support visceral or tumor protein synthesis is believed to
be crucial. An unnatural PFAA pattern might be shown
through the total reflection of cancer-induced protein me-
tabolism in tumors, the liver and skeletal muscle in cancer
patients [12]. A study from France reported that surgical
tumor removal induced a normalization of aminoacidemia
[42]. However, the effect of surgery and wound healing
process after surgical trauma on amino acid metabolism
and PFAA profile is still unclear. An animal study has
shown that pulmonary blast injury induces prompt
arginine elevation through NO synthase [43]. Moreover, a
persistent drop of arginine, which contributes to T cell
dysfunction and decrease of nitric oxide (NO) production,
was found to significantly increase susceptibility to infec-
tions and organ failure after trauma or surgery. Dietary
therapy containing arginine at supra-physiologic levels
along with other components is related to improvements
in Tcell function, NO production, and a significant decrease
in infection rates [44]. Therefore, deeper understanding of
perioperative dynamic PFAA profile is also important for
better recovery from surgery.
Genomics and proteomics are used to identify many
blood-based biomarkers of GC and BC. A small genomic
and proteomic changes can be amplified multiple times
at the metabolite level and quantitatively measured [45].
In our study, most of BC and TC subjects are defined at
relative early stages, and their clinical blood samples re-
vealed no anomalies. However their PFAA profiles were
significantly different from the control group. In the GC
patients’ group, some PFAAs levels were correlated with
typical tumor markers such as CEA and CA19-9. These
results suggested that tumor-specific amino acids identi-
fied by PFAA profiling may be potential accomplishment
for early cancer detection. In addition, PFAA profile was
correlated with expression of ER, PR, HER2 and Ki-67
in BC patients, which are critical for treatment choices
and clinical outcomes [46,47]. Some AAs were associ-
ated with negative prognostic markers as Ki-67 but
others with hormone factors which implies good prog-
nosis. These results indicate biological function of each
amino acid varies during tumor progression. This might
also be due to the upstream genomic and proteomicchange and provide potential classification information
before surgery.
To further study the mechanism of cancer-related
PFAAs, we found Ala and Glu were pro-apoptotic GC
cells as evidenced by flow cytometry and MMP assay.
These data are also consistent with data obtained from
CCK-8 and Cell-IQ assays. Previous studies have re-
ported that Ala and Glu were significantly up-regulated
in apoptotic HepG2 and HEK293 cells and they may be
relevant signature molecules of apoptosis. The increase
of Ala and Glu in apoptotic cells was explained by their
association with taurine metabolism [48]. However, Ala
showed opposite effects on BC cells by promoting cells
proliferation, which indicates the cancer type-specific
role of Ala. Ala is the key protein-derived glucose pre-
cursor used by the liver [49]. The decrease of plasma
Ala concentration in the GC group supports the notion
that tumor malignancy is associated with an increase
in gluconeogenesis [50]. Ala was found to be protective
against acute liver failure and melanoma [24,51]. As
for breast cancer, elevation of Ala concentrations may
enhance gluconeogenesis and promote proliferation of
breast cancer cells in vitro. However, no significant alter-
ation of plasma Ala level was seen in BC patients group.
Studies with large sample volume are needed to further
explore the tumor type-specific role of Ala in different
types of cancer. It should also be noted that the tumor
microenvironment made up of various immune and
stroma cells influence amino acid metabolisms in tumor
cells. Poschke and colleagues discovered tumor-dependent
impact of breast cancer on serum AA levels, and
positive correlation of certain amino acid levels and pro-
inflammatory immunological factors and a more aggres-
sive intrinsic tumor subtype [52]. Our in vitro findings
should be further investigated in animal models or human
tumor samples.
Since PFAAs are biosynthesized in an interrelated
fashion, the PFAA profile is a complex network contain-
ing rich amount of information. For instance, Ala and
Pro are biosynthesized from Glu via aminotransferase
[53]. Tumor growth requires Glu, Gly, Asp and ammo-
nia for purine and pyrimidine synthesis, which brings a
selective demand on these metabolites [54]. Actually,
our data showed that the levels of these amino acids in
patients with different cancers were lower than those of
healthy individuals. Arg has long been recognized as an
essential nutrient for tissue healing and a critical compo-
nent of immunonutrition [55]. More importantly, there
is evidence suggesting that Arg stimulates tumor growth
[56]. We found Arg levels raised in all patient subjects.
We also found that plasma level of BCAAs in GC
patients was significantly lower than that of healthy
subjects. BCAAs, oxidized peripherally, serve as a source
of fuel to decrease protein degradation and stimulate
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level of BCAAs tends to decrease in patients with
advanced liver cirrhosis [58]. Our results may indicate
disrupted liver function in GC patients.
Unlike transcripts or proteins with multiple modifica-
tions, each amino acid is uniquely stable and the entire
amino acids family is relatively small in humans. In
addition, PFAA alterations may amplify the upstream
fine tuning. From our results, we demonstrated that
PFAA profiling might be developed as a promising diag-
nostic method for cancer patients. However, additional
large-scale studies are required to fully evaluate clinical
utility of this profile. Furthermore, integrating novel dis-
covery of clinical and laboratory study provides better
understanding on biological function of cancer type-
specific amino acids for gastric cancer and breast cancer.
The integrative analysis of clinical informatics and novel
biomarkers may generate more meaningful studies in
translational medicine [59,60].
Conclusions
PFAA patterns of cancer patients are dynamically altered
during the perioperative period. Tumor-related amino
acids identified by dynamic study of PFAA pattern might
be promising biomarkers for diagnosis of cancer patients.
Their biological effects on cancer cell proliferation are
worth further evaluation for metabolic treatment in the
future.
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